Neurocrine Biosciences Inc. (NBIX) Offers a Solid Product Pipeline and a Probable $575 Million Development Deal with Abbott Labs
One of the real tricks to investing in the bioscience sector is finding a company with a solid research arm, solid relationships with big pharma and a solid product pipeline that is ready to pump out product at regular intervals. If one can do this, a profit will most likely be had. Neurocrine Biosciences Inc., a developer and commercialize of endocrine and neurological based pharmaceutical products, works to develop and commercialize a wide variety of products. The company currently has several products in phase II FDA testing and several others that have received FDA indicators with positive approval status (with…